Pharma Focus Asia

Everest Medicines Has Received Approval for the New Drug Application (NDA) for Nefecon® in Taiwan, Aimed at Treating Primary IGA Nephropathy in Adult Patients

Wednesday, December 27, 2023

Everest Medicines (HKEX 1952.HK) has declared that the Taiwan Food and Drug Administration (TFDA) has accepted its New Drug Application (NDA) for Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® is the first treatment for IgAN approved in the U.S., European Union, and mainland China. The company expects approval in Taiwan in 2024.

Rogers Yongqing Luo, CEO of Everest Medicines, expressed satisfaction with the expansion to Taiwan after recent NDA approvals in China and NDA acceptance in South Korea. The Asian population has a high prevalence of IgAN, posing a significant risk of progression to end-stage renal diseases.

Nefecon® received Accelerated Approval Designation (AAD) from the Taiwan FDA in Nov. 2022. The Phase 3 NefIgArd clinical trial demonstrated statistically significant and clinically meaningful benefits of Nefecon® over placebo in preserving kidney function for patients with IgAN.

The full two-year results of the NefIgArd trial, involving 364 patients, showed clinically meaningful preservation of kidney function in both Asian and White subgroups. Everest Medicines aims to offer Nefecon® to patients in various Asian territories in 2024, including Singapore, Hong Kong, Taiwan, and South Korea.

Nefecon® is a patented oral, delayed-release formulation of budesonide, a corticosteroid designed to target mucosal B-cells in the ileum where IgAN originates. Everest Medicines holds exclusive rights to develop and commercialize Nefecon® in Mainland China, Hong Kong, Macau, Taiwan, Singapore, and, as of March 2022, South Korea, through a licensing agreement with Calliditas Therapeutics AB.

 

Source: prnewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024